New advances in targeted therapy for breast cancer
10.3760/cma.j.cn112152-112152-20190919-00614
- VernacularTitle:乳腺癌靶向治疗新进展
- Author:
Jing ZHAO
1
;
Nan WU
;
Shichao ZHANG
;
Ziwei ZHAO
;
Lijuan LI
;
Juntian LIU
Author Information
1. 天津医科大学肿瘤医院乳腺科 国家肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心 乳腺癌防治教育部重点实验室 300060
- Keywords:
Breast neoplasms;
Targeted therapy;
Molecular subtype;
Development
- From:
Chinese Journal of Oncology
2020;42(5):353-361
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Breast cancer is a kind of malignant tumor which seriously endangers women′s health. With the development of molecular biology technology and the further understanding of pathogenesis, the treatment of breast cancer has entered a new era of molecular targeted therapy, and has been making new progress. At present, molecular targeted drugs for the treatment of breast cancer keep emerging, mainly including endocrine therapy targeting estrogen and progesterone receptor (ER/PR), targeted drugs treatment for epidermal growth factor receptor-2 (HER-2); phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway inhibitors, anti-angiogenic drugs, poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA1/2 mutations, cyclin-dependent kinases (CDK) 4/6 inhibitors, etc. Because some signal pathway abnormalities may occur in different molecular types of breast cancer, the same targeted drugs are cross-used in different types.
